HC Wainwright Issues Optimistic Forecast for JSPR Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Investment analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for Jasper Therapeutics in a report issued on Tuesday, May 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.53) for the quarter, up from their prior forecast of ($1.59). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.95) EPS, FY2025 earnings at ($6.65) EPS, FY2026 earnings at ($7.96) EPS, FY2027 earnings at ($9.29) EPS, FY2028 earnings at ($10.38) EPS and FY2029 earnings at ($10.49) EPS.

Separately, UBS Group reduced their price target on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has an average rating of “Buy” and a consensus price target of $61.88.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $4.85 on Thursday. The stock’s fifty day simple moving average is $4.62 and its 200 day simple moving average is $11.24. Jasper Therapeutics has a one year low of $3.13 and a one year high of $26.84. The firm has a market cap of $72.86 million, a price-to-earnings ratio of -1.02 and a beta of 2.74.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its holdings in shares of Jasper Therapeutics by 12.6% during the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock valued at $316,000 after purchasing an additional 1,652 shares in the last quarter. Barclays PLC raised its holdings in Jasper Therapeutics by 13.6% during the 4th quarter. Barclays PLC now owns 18,334 shares of the company’s stock worth $392,000 after buying an additional 2,188 shares during the period. Wellington Management Group LLP lifted its stake in Jasper Therapeutics by 13.9% in the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock valued at $579,000 after buying an additional 3,310 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after buying an additional 3,828 shares during the period. Finally, Rock Springs Capital Management LP increased its position in shares of Jasper Therapeutics by 0.9% during the fourth quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company’s stock worth $9,901,000 after acquiring an additional 4,000 shares in the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.